Biotest AG (BIO.DE) Stock Analysis & Winston Score

Biotest AG is a German biotechnology company that makes medicines from human blood plasma. Its main products are plasma-derived therapies — including immunoglobulins, clotting factors, and albumin — used to treat patients with immune deficiencies, bleeding disorders, and serious infections. The company sells primarily to hospitals and clinics, and it is a mid-sized player in the global plasma products market, which is dominated by a small number of specialized manufacturers. Biotest earns revenue by collecting or sourcing human plasma, processing it into finished medical products, and selling those products to healthcare providers across Europe and other international markets. The company is majority-owned by the Chinese firm Creat Group, which acquired control in 2018. Its competitive position depends on its plasma processing infrastructure and product licenses, which are difficult and expensive to replicate. The key risk is its very thin operating margin, which leaves little room for error if raw plasma costs rise or pricing pressure increases from larger rivals.